Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.

Abstract: Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.

Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.

Abstract: This disclosure relates generally to proteins target tumor cell killing comprising: a polypeptide or complex of two or more polypeptides that specifically binds ROR1, and a polypeptide or complex of two or more polypeptides that specifically binds CD3. In some embodiments, the present application provides antibodies that specifically bind ROR1. In some embodiments the application also provides therapeutic methods for using such proteins in the treatment of a cancer.

Abstract: VHH-based NKp30 binders are provided having favorable characteristics. Moreover, pharmaceutical compositions including such a compound are produced and methods of medical treatment with such compounds and pharmaceutical compositions are developed. In a compound including a VHH antibody domain or fragment thereof, the VHH antibody domain or fragment thereof can have complementary determining regions CDR1, CDR2, and CDR3 of one of VHH1 to VHH16, or a humanized modification thereof, or a modification involving replacement, addition, and/or deletion of up to three amino acids in each complementary determining region.

Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).

Abstract: Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.

Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).

Abstract: Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: B7-H6-based compounds disclosed herein have favorable characteristics. Pharmaceutical compositions containing such a compound, the use of such compounds, and treatment with such pharmaceutical compositions are also disclosed. Methods for preparing a compound with an increased affinity for NKp30 are provided.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).

Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.

Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.